



ACTIVITY REPORT

2000-2001



OUR MISSION

HÉMA-QUÉBEC's mission is to provide Québeckers with sufficient quantities of safe, top-quality blood components, derivatives and blood substitutes to meet the needs of hospitals, and to provide recognized expertise and specialized services in the field of immunohematology.



3	Our mission
5	Message from the Executive Director
8	2000–2001 highlights
	– Risk management and measures taken to improve the safety of the blood supply
	– Measures taken to improve efficiency
	– Human resources
	– Research projects
	– Networking with volunteers: Development of the volunteer training program
	– Outreach
	– Code of Ethics and Professional Conduct
20	Blood donor clinics and deliveries to hospitals
22	Publications
23	Scientific papers
25	Corporate presentations
26	Continuing medical education
27	Financial statements for the year ended March 31, 2001
45	Board of Directors and committee members as of March 31, 2001

MESSAGE FROM THE EXECUTIVE DIRECTOR



HÉMA-QUÉBEC entered a significant stabilization period during 2000–2001. A November 2000 management restructuring—which included the creation of a human resources department headed by a senior director—successfully laid the groundwork for a company-wide shift, driven by a win-win approach, and which we have dubbed HÉMA-QUÉBEC version 2.

As you will read in the following pages, HÉMA-QUÉBEC also introduced a series of measures during the year aimed at making continuous improvements to the safety of the blood supply, such as nucleic acid testing (NAT) for human immunodeficiency virus (HIV) and new exclusion criteria for donors having spent an extended period of time in France. We also took some initial steps toward carrying out a pilot project involving plasma self-sufficiency. In addition, the Hématech testing group began its operational research work.

Other achievements during the year included measures aimed at improving internal efficiency and performance—for example, the definition of management indicators and preliminary efforts at establishing a five-year strategic planning procedure. None of these many activities, however, would have been accomplished without the thoroughness and effort of our highly qualified and devoted staff and management team.


The main reason HÉMA-QUÉBEC has been able to fulfill hospitals' requirements in terms of labile blood products is the tireless support of the

donors who answer the needs of their fellow citizens by giving blood. Not to be overlooked is the vital role played by the thousands of volunteers who organize blood donor clinics and donor recruitment drives. We are grateful to them.

Lastly, we would like to emphasize the fine example of leadership demonstrated by the Board of Directors and its advisory committees in ensuring the safety of the blood supply.

All in all, 2000–2001 has been a pivotal year. A significant number of initiatives has been implemented to help us realize our vision: to be the North American leader in our field by 2005.

Therefore, I would like to extend my warmest thanks to all those who allow us to make this vision of our organization a bit more of a reality, each and every day. I believe that we can all be extremely proud of our accomplishments.



Dr. Francine Décaré
Executive Director



ANNE-MARIE Transfused 122 times

2000-2001 HIGHLIGHTS

RISK MANAGEMENT AND MEASURES TAKEN TO IMPROVE THE SAFETY OF THE BLOOD SUPPLY

VARIANT CREUTZFELDT-JAKOB DISEASE (vCJD)

In keeping with the spirit of the Krever Report and in accordance with a Health Canada directive, on October 30, 2000, HÉMA-QUÉBEC began excluding all blood donors having spent six months or more in France, whether cumulatively or consecutively, between 1980 and 1996 inclusively. The measure was implemented even though there is only a hypothetical risk of vCJD transmission through blood transfusion.

This measure is part of ongoing efforts to monitor variant Creutzfeldt-Jakob disease. Previously, in September 1999, HÉMA-QUÉBEC had moved to exclude all prospective donors having spent a cumulative total of 30 days or more in the United Kingdom since 1980.

In France, the number of confirmed cases of vCJD thus far reported stands at three. The French nationals involved had not travelled to the U.K. The current working hypothesis is that so-called mad cow disease is transmitted to humans via the consumption of contaminated meat. It has now been established that between 5% and 10% of the beef consumed in France from 1980 to 1996 originated in the U.K. France ceased imports of U.K. beef in 1996.

Since it was implemented, this measure has affected approximately 2.5% of prospective donors.

NUCLEIC ACID TEST (NAT) FOR HIV

On January 17, 2001, pursuant to a research protocol, HÉMA-QUÉBEC began an assessment of the operational impact of a new technology for detecting the presence of the HIV virus. This test is designed to detect the virus itself.

The advantage of this new technique is a considerable reduction of the so-called window period, during which time it is still impossible to detect the presence of the virus. Findings from U.S. studies indicate that the NAT could

lead to a reduction of approximately 25% in the window period (i.e., the time between initial infection and the appearance of antibodies).

As of March 31, 2001, around 58,000 donor samples had been analysed, with none testing positive for HIV using the NAT. This fact alone confirms the high level of safety of the blood donor selection process already in place. Testing is done by the Québec City-based firm Infectio Diagnostic inc.

PLASMA SELF-SUFFICIENCY

In 2001, the HÉMA-QUÉBEC Board of Directors approved plans to design and implement a plasma self-sufficiency pilot project. The structure for developing the outline of this pilot project is now in place.

DISASTER RECOVERY PLAN — PROGESA

During 2000–2001 the Information Technology department outlined a disaster recovery plan—also known as a continuity plan—for the PROGESA software system. The plan is designed to ensure HÉMA-QUÉBEC's capability to maintain operations in case of an incident such as a fire or power outage, or following a natural disaster. Several simulations were conducted during the year to validate the procedures and methods developed. The plan was presented to Health Canada's Bureau of Biologics and Radiopharmaceuticals (BBR).

TRAINING IN GOOD MANUFACTURING PRACTICES AND GOOD WORK PRACTICES

On May 11, 2000, HÉMA-QUÉBEC implemented an employee training program focussing on Good Manufacturing Practices and Good Work Practices (GMP/GWP). Compliance with Good Manufacturing Practices is an essential condition for renewal of HÉMA-QUÉBEC's operating licence. During the year, all staff members received two and a half days of training on GMP/GWP-related principles, with the aim of strengthening their commitment to quality in all aspects of their work. The concepts learned were reinforced during the year via a GMP/GWP awareness campaign.

HÉMATECH TESTING GROUP

Created last year and presided over by the Senior Director, Research and Development, the Hématech group began its job of supervising operational research work in 2001 to test, optimize and validate new technologies. This year, the Hématech group conducted three studies in collaboration with the Operations and Medical Affairs departments:

1. validation of sampling devices with derivation of initial millilitres of blood;
2. screening of immunoglobulin A(IgA)-deficient donors;
3. assessment of new cell separators for thrombapheresis.

These studies, slated to be completed during 2001–2002, will help to demonstrate the important role that the Hématech group can play in the assessment by HÉMA-QUÉBEC of new technologies, as well as in the operational implementation of those technologies.

RENEWAL OF BUREAU OF BIOLOGICS AND RADIOPHARMACEUTICALS (BBR) LICENCE

BBR inspectors renewed HÉMA-QUÉBEC's licence following the yearly procedural audit, which took place between December 4 and 8, 2000 at the Québec City facility, and between January 31 and February 9, 2001 at the Montréal facility.

Throughout the audit, the BBR inspectors were able to see that the safety of blood components is the top priority for all HÉMA-QUÉBEC personnel.

AMERICAN ASSOCIATION OF BLOOD BANKS (AABB) ACCREDITATION

On March 1, 2001, HÉMA-QUÉBEC secured AABB accreditation. This formal recognition is the outcome of an exhaustive evaluation procedure entrusted to specially trained AABB representatives. Their mandate is to assess blood bank and transfusion service operations, along with their medical, technical and administrative practices, to determine whether they meet or exceed the standards set by the AABB. HÉMA-QUÉBEC satisfied all of these requirements, and thus joined the ranks of the approximately 2,000 agencies accredited by the AABB in the United States and internationally.



JONATHAN Transfused 44 times

SERUM BANK SAMPLE ANALYSIS

The mandate of the team assigned to serum bank sample analysis ended on September 5, 2000. As part of the serum bank project, a team of six HÉMA-QUÉBEC technicians and assistant technicians spent close to a year analysing more than 176,000 blood samples collected between April 1988 and May 1992.

The goal of the serum bank project was to test for the Hepatitis C virus in individuals who had never made a repeat blood donation after May 1992, when second-generation tests to detect the virus were introduced. The serum bank project took place at the Laboratoire de santé publique du Québec, which had lent laboratory space to HÉMA-QUÉBEC for the project.

The tests identified 384 donors who were found to be carriers, and these people were notified by mail. Studies of earlier donations were then ordered for all donors testing positive. To date, notification has been transmitted to hospitals regarding a total of 1,161 labile blood products prepared from infected donor samples and delivered to hospitals.

EPIDEMIOLOGY UNIT

The HÉMA-QUÉBEC Medical Affairs department implemented a new service called the epidemiology unit. Its mandate is to produce a monthly demographic report, including a statistical profile of donors, information on donor bans, and results of qualifying tests. This report is distributed internally and is also filed with the Haemovigilance Committee.

QUALITY CONTROL

HÉMA-QUÉBEC has now integrated the following into its quality control operations: frozen products (factor VIII and fibrinogen) and serum protein electrophoresis for plasmapheresis donors. These two services were previously provided by Canadian Blood Services (CBS).

MEASURES TAKEN TO IMPROVE EFFICIENCY

FIVE-YEAR STRATEGIC PLAN

In 2000–2001, HÉMA-QUÉBEC began to implement a strategic planning process with a view to achieving its corporate vision: to be the North American leader in its field by 2005.

Among the activities undertaken was the implementation of a project management system, which tracks all in-progress projects and enables us to thoroughly monitor those projects identified as priority by the Management Committee. Management also adopted a structured approach to risk management, which made it possible to draw up an inventory of all risks, sorted by order of frequency.

As part of the strategic planning process, each senior director was asked to complete a list of annual objectives. This is a first step leading to a performance evaluation process that will eventually be applied throughout the corporation.

MANAGEMENT INDICATORS

During the year 2000–2001, HÉMA-QUÉBEC identified a dozen or so management indicators to be used to assess corporate performance in all of its spheres of activity. The indicators were selected by a multidisciplinary team made up of staff members representing all hierarchical levels.

INFORMATION SYSTEM OPTIMIZATION AND SECURITY

A series of measures was taken with a view to optimizing and enhancing the security of the corporation's information and telecommunications systems. To this end, the Information Technology department developed new procedures affecting, among other things, changes to users' passwords, information backup, and data access to the internal network.



CATHERINE Transfused 22 times

HUMAN RESOURCES

INTRODUCTION OF AN ORIENTATION PROGRAM FOR NEW EMPLOYEES

In January 2001, HÉMA-QUÉBEC introduced a new employee orientation program to smooth the arrival and integration of new staff members. The orientation program includes an employee handbook which provides an overview of the corporation, its policies and procedures, as well as guidelines for the immediate supervisor whose task it is to welcome a new employee.

INTEREST-BASED NEGOTIATIONS

In April 2000, management approved the creation of a negotiation team as part of the planned shift to a new corporate culture grounded in a win-win approach.

The Human Resources department will play a fundamental role in ensuring a smooth transition to this new corporate culture—in particular, by developing a planned approach to human resources management.

As an initial step in this approach, HÉMA-QUÉBEC introduced an interest-based method of negotiation with union representatives in April 2000. The goal is to facilitate better mutual understanding within the corporation. The basic tenets of this approach are: make it a priority to identify each party's concerns; exchange information within an atmosphere of trust; and explore consensus-building solutions.

HALTE-RESSOURCES

On May 11, 2000, in Saint-Hyacinthe, all HÉMA-QUÉBEC personnel took part in an inaugural training and information day organized for their benefit and dubbed "Journée Halte-Ressources." The morning session focussed on training in Good Manufacturing Practices and Good Work Practices (GMP/GWP), provided by the HÉMA-QUÉBEC Training department, while the afternoon was devoted to an information session examining the missions of each of the corporation's divisions. The organization of this event was made possible thanks to the substantial support of two of our suppliers.

RESEARCH PROJECTS

The Board of Directors approved a strategic development plan for the Research and Development department, following the recommendation of the Comité consultatif médical et scientifique (CCMS), the Medical and Scientific Advisory Committee. In October 2000, the CCMS approved the inception of a new project involving blood-cell cultures in a bioreactor. It also deemed satisfactory the progress made over the past year in the 12 projects authorized in 1999.

The HÉMA-QUÉBEC Comité d'éthique de la recherche (CER), the Research Ethics Committee, came into its own this past year and began to review research and development projects that require the use of human blood and the participation of volunteer donors. The CER held five meetings in 2000–2001, approving 12 research projects.

NETWORKING WITH VOLUNTEERS: DEVELOPMENT OF THE VOLUNTEER TRAINING PROGRAM

In collaboration with HÉMA-QUÉBEC, the Association des bénévoles du don de sang (ABDS), the Association of Blood Donation Volunteers, set up a training and information program for the supervisors of its 10 regional councils. The initial purpose of the program is to provide tools to trainers, who in turn will be equipped to advise groups across Québec that promote the importance of giving blood. Particular attention is paid to training first-time donors and volunteers.

It is worth recalling the shared objectives of the Association and HÉMA-QUÉBEC. First, those that involve donors: the goal is to recruit new, primarily young, donors and to build loyalty by encouraging regular donors to make one more donation per year. Next, those that affect both donors and volunteers: efforts are made to mobilize them within their community, to support teams, and to invite non-donors to give in other ways—for instance, by giving of their time, donating money, or through various types of sponsorship.

OUTREACH

RESEARCH AND DEVELOPMENT OPEN HOUSE

On February 13, 2001, the Research and Development department, in collaboration with the Public Relations department, welcomed media representatives to its laboratories at 2535 Laurier Blvd. in Sainte-Foy, as part of an open house. Representatives from both print and electronic media outlets were thus able to learn more about the raison d'être and content of HÉMA-QUÉBEC research programs.

OVATION AWARD

HÉMA-QUÉBEC took home a Merit Distinction prize at the Ovation awards, organized by the Montréal chapter of the International Association of Business Communicators. The prize underlines the excellent work performed by the public relations team, with the help of the steering committee, in developing and implementing the communications plan related to the installation of Mak System's PROGESA blood management software.

CANADIAN SOCIETY FOR TRANSFUSION

MEDICINE / HÉMA-QUEBEC / CANADIAN BLOOD

SERVICES JOINT CONFERENCE

HÉMA-QUÉBEC hosted the Joint Conference of the Canadian Society for Transfusion Medicine, HÉMA-QUÉBEC, and Canadian Blood Services, held at the Château Frontenac in Québec City from May 4 to 7, 2000. Under the banner "Expanding Horizons," the conference welcomed more than 360 participants, 55% of whom were from Québec, 40% from elsewhere in Canada and 5% from the United States.

Conference attendees included physicians, nurses, scientists, blood bank technicians and industry representatives with an interest in transfusion medicine. Renowned lecturers from Canada, the United States and Europe were on hand to address such current topics as hemovigilance, prions, genome amplification testing (GAT), and international standards for transfusion medicine. The event was funded in part by the Québec Ministère de la Recherche, de la Science et de la Technologie and Canadian Heritage.



XIOMARA Transfused 2 times

LABORATORY TOURS AT THE MONTRÉAL FACILITY

Representatives of several blood suppliers from Canada and the United States toured the Montréal facility's transformation laboratories at 3131 Sherbrooke Street East and studied the efficient workflow implemented by HÉMA-QUÉBEC for leukoreduction procedures.

CODE OF ETHICS AND PROFESSIONAL CONDUCT

The HÉMA-QUÉBEC Code of Ethics and Professional Conduct was published as part of the HÉMA-QUÉBEC corporate brochure. It should be emphasized that during 2000–2001, there were no occurrences of situations requiring application of the Code.

BLOOD DONOR CLINICS AND DELIVERIES TO HOSPITALS

TABLE 1
Clinics and Collections between April 1, 2000 and March 31, 2001

Number of clinics held	2,449
Number of donors expected	292,715
Number of donors received	269,952
Number of donors excluded	45,777
Number of bags of blood collected	224,175

TABLE 2
Labile Products Delivered

	Hospitals	CBS
Packed red blood cells	200,747	566
Platelets	108,040	1
Platelets—apheresis	1,702	—
Plasma	40,138	—
Cryoprecipitate	11,935	—
Cryoprecipitate supernatant	6,069	270
TOTAL	368,631	837

TABLE 3
Labile Products Received

	CBS
Packed red blood cells	1,071
Platelets	306
Platelets—apheresis	1
Plasma	17
Cryoprecipitate	90
Cryoprecipitate supernatant	777
TOTAL	2,262



ELIZABETH Transfused 56 times

PUBLICATIONS

- BLAJCHMAN (M.A.), GOLDMAN (M.), FREEDMAN (J.J.), SHER (G.D.). Proceedings of a Consensus Conference: Prevention of post-transfusion CMV in the era of universal leukoreduction, *Transfusion Medicine Reviews* 2001, 15(1), 1-20.
- BOUCHARD (M.), ST-AMAND (J.), CÔTÉ (S.). Combinatorial activity of pair-rule proteins on the *Drosophila* gooseberry early enhancer, *Dev. Biol.* 2000, 222, 135-46.
- DÉCARY (F.). Transferring donor loyalty to a new blood system operator: HÉMA-QUÉBEC's experience, *Vox Sanguinis* 2000, 78(suppl. 2), 303-05.
- ENGELFRIET (C.P.), REESINK (H.W.), GARRATY (G.), KNIGHT (R.), DE SILVA (M.), CONTRERAS (M.), OVERBEEKE (M.A.M.), PORCELIJN (L.), LIN (M.), SO (C.C.), SCHMIDT-MELBYE (A.C.), HEIER (H.E.), SOKOL (R.J.), BOOKER (D.J.), STAMPS (R.), BARBOLLA (L.), ZAMORA (C.), HERNÁNDEZ-JODRA (M.), ZUPANŠKA (B.), GOLDMAN (M.), LONG (A.), DÉCARY (F.). International Forum: The detection of alloantibodies against red cells in patients with warm-type autoimmune haemolytic anaemia, *Vox Sanguinis* 2000, 78, 200-07.
- GERMAIN (M.). Dépistage du VHC par test d'amplification des acides nucléiques (TAN) chez les donneurs de sang à HÉMA-QUÉBEC, *L'AMMIQale* 2000, 8(3).
- GERMAIN (M.), DÉCARY (F.), CHIAVETTA (J.), GOLDMAN (M.). Variant Creutzfeldt-Jakob disease and the Quebec blood supply, *Journal de l'Association médicale canadienne*, 22 August 2000, 163(4), 412-13.
- GOLDMAN (M.), LONG (A.). Hepatitis C lookback in Canada, *Vox Sanguinis* 2000, 78(suppl. 2), 249-52.
- GOLDMAN (M.), SHER (G.), BLAJCHMAN (M.). Bacterial contamination of cellular blood products: The Canadian perspective, *Transfusion Science* 2000, 23, 17-19.
- GOLDMAN (M.), SPURLL (G.). Hepatitis C lookback, *Current Opinion in Hematology* 2000, 7, 392-96.
- JUNG (D.), NÉRON (S.), LEMIEUX (R.), ROY (A.), RICHARD (M.). Telomere-independent reduction of human B lymphocyte proliferation during long-term culture in the CD40-CD154 system, *Immunological Investigation* 2001, 30(2), 157-68.
- SHER (G.), BOYCE (N.W.), CHIAVETTA (J.), SCHURER (W.), O'BRIEN (S.), GOLDMAN (M.). Blood collection and utilization in Canada, 1987-1998, *Bulletin de la SCMT* 2000, 12(3), 116-22.
- SLINGER (R.), GIULIVI (A.), BODIE-COLLINS (M.), HINDIEH (F.), ST. JOHN (R.), SHER (G.), GOLDMAN (M.), RICKETTS (M.), KAIN (K.C.). Transfusion-transmitted malaria in Canada, *Journal de l'Association médicale canadienne* 2001, 164(3), 377-79.

SCIENTIFIC PAPERS

TSE ADVISORY COMMITTEE

FDA

WASHINGTON, MAY 2000

GERMAIN (M.) MD, PHD, HÉMA-QUÉBEC,
CHIAVETTA (J.) PHD, Canadian Blood Services. *The Burden of Exposure of Canadian Blood Donors to Beef Products Originating from the United Kingdom.*

CANADIAN SOCIETY FOR TRANSFUSION

MEDICINE CONFERENCE

QUÉBEC CITY, MAY 2000

PAPERS

BAZIN (R.), ST-AMOUR (I.), BOYER (L.), ROBERGE (C.), LEMIEUX (R.). *Biological Activity of Human Monoclonal Anti-Rh(D) antibodies in a NOD-scid mouse model* [abstract published in *Transfusion Medicine*, 2000, 3].

GERMAIN (M.). *Prospective Evaluation of a Universal Screening Program for Hepatitis C Virus by Nucleic Acid Testing (NAT) among HÉMA-QUÉBEC Blood Donors.*

PROULX (C.), HURNANEN (D.), LEMIEUX (R.). *Proliferation of Megakaryocyte Progenitors in Ex Vivo Cultures of Cord Blood Hematopoietic Cells.*

PROULX (C.), HURNANEN (D.), LEMIEUX (R.). *Ex Vivo Expansion of Cord Blood CD34-Enriched Cells in Suspension Cultures.*

THIBAUT (L.), BAZIN (R.), BEAUSÉJOUR (A.), LEBLANC (J.-F.), ST-LAURENT (M.), LEMIEUX (R.). *Effects of Intrinsic Affinity on the Relative Reactivity of IgM and IgG Blood Group Antibodies.*

POSTERS

CHÂTEAUNEUF (I.), AUBIN (S.), NÉRON (S.), LEMIEUX (R.), BAZIN (R.). *Modulation of Apoptosis Susceptibility and of Related Gene Expression during Continuous Culture of Human B Cells**

CHEVRIER (M.-C.), CHÂTEAUNEUF (I.), LEMIEUX (R.). *Development of Highly Effective Peroxidase-Conjugated Anti-Human IgG Monoclonal Antibody.*

CÔTÉ (S.G.), BAZIN (R.), LEMIEUX (R.), SIMARD (C.), BOYER (L.). *Expression of Apoptosis-Related Genes in IL-6-Dependent Murine Myeloma Cells.*

CÔTÉ (S.G.), LEMIEUX (R.), SIMARD (C.), ROBERGE (C.). *Identification of Genes Regulated by the Cytokine Interleukin-6 in Hybridoma Cells*

DÉCARY (F.). *Application des principes de transparence et d'accessibilité à HÉMA-QUÉBEC.*

DÉCARY (F.), BERNIER (F.), LÉVEILLÉ-DESIARDINS (J.). *Dépistage de l'hépatite C dans une sérothèque de 1988 à 1992.*

DUPUIS (N.), THIBAUT (L.), CHEVRIER (M.-C.), NOLIN (M.-E.), LEMIEUX (R.). *Hybridoma Cell Line-Dependent Increase of mAb Productivity in Perfusion over Batch Culture System.*

FECTEAU (J.), BAZIN (R.), LEMIEUX (R.), NÉRON (S.). *Evaluation of Memory B-Cells Growing Capacity in the CD40-CD154 System*.*

JUNG (D.), LEMIEUX (R.), DROUIN (M.). *Development of a Suitable Assay for Large Scale PRNP M/V Genotyping at Codon 129.*

JUNG (D.), NÉRON (S.), RICHARD (M.), ROY (A.).
*Telomere-Independent Gradual Senescence of B Lymphocytes during Prolonged Culture in the CD40 System**.

NÉRON (S.), LEMIEUX (R.), ROY (A.), FECTEAU (J.).
*Polyclonal Expression of Immunoglobulin Genes in Cultured Human B-Lymphocytes**.

M. RAYNOR (C.), KRZYKWA (E.), NÉRON (S.), LEMIEUX (R.), PRYZDIAL (E.L.G.), *Apoptosis and Necrosis in Hybridoma Cells Are Inhibited by bcl-XL**.

THIBAUT (L.), LEMIEUX (R.), BEAUSÉJOUR (A.).
Development of an IgA-specific ELISA for the Screening of IgA-Deficient Blood Donors.

**XXTH CONFERENCE OF THE SOCIÉTÉ
FRANÇAISE DE TRANSFUSION SANGUINE
PARIS, JUNE 2000**

GERMAIN (M.). *L'implantation d'un critère de sélection des donneurs québécois potentiellement à risque pour la variante de la maladie de Creutzfeldt-Jakob (vMCJ).*

GERMAIN (M.), POULIN (L.), DÉCARY (F.). *Programme de dépistage du virus de l'hépatite C par recherche de l'ARN viral sur des pools d'échantillons de plasma chez les donneurs de sang à HÉMA-QUÉBEC.*

GOLDMAN (M.), DEMERS (H.). *Bilan des enquêtes sur les infections reliées à la transfusion, hépatite B, 1992-1999, HÉMA-QUÉBEC.*

**29TH ANNUAL SCIENTIFIC MEETING OF
THE INTERNATIONAL SOCIETY FOR
EXPERIMENTAL HEMATOLOGY
TAMPA, JULY 2000**

PROULX (C.), HURNANEN (D.), LEMIEUX (R.). *Ex Vivo Expansion of Cord Blood Megakaryocytic Cells**.*

**26TH CONGRESS OF THE ISBT
VIENNA, JULY 2000**

GERMAIN (M.), POULIN (L.), DÉCARY (F.). *A Stepwise Strategy for Implementing Universal Screening of Blood Donors for HCV by Nuclear Acid Testing (NAT): The HÉMA-QUÉBEC Experience.*

GOLDMAN (M.), ROY (G.), CHIROUX (S.), DÉCARY (F.), PRICE (K.), SHAMY (A.). *Severe Thrombocytopenia Post-Transfusion of FFP Containing Anti-HPA-1a.*

**CONGRESS OF THE INTERNATIONAL
SOCIETY OF HEMATOLOGY (ISH)
TORONTO, AUGUST 2000**

DÉCARY (F.). *Transferring Donor Loyalty to a New Blood System Operator: HÉMA-QUÉBEC's Experience.*

**CURRENT TOPICS IN GENE
EXPRESSION SYSTEMS
SAN DIEGO, SEPTEMBER 2000**

POSTER

CÔTÉ (S.), JUNG (D.), LEMIEUX (R.), SIMARD (C.), DROUIN (M.). *Use of a Metal-Inducible Expression Vector with pcDNA3.1 Backbone in Hybridoma Cell Cultures*

**AMERICAN ASSOCIATION OF BLOOD
BANKS, 53RD ANNUAL MEETING
WASHINGTON, NOVEMBER 2000**

PAPERS

BAZIN (R.), LEMIEUX (R.). *Biological Activity of Human Monoclonal Anti-Rh(D) Antibodies in a NOD-Scid Mouse Model***.*

GOLDMAN (M.). *What Is the Risk of Transfusion-Transmitted Bacterial Infection?*

POSTERS

BAZIN (R.), BOUILLON (M.), LEMIEUX (R.). *Increased Specificity of HIV Antibody EIA Following Elution of Natural Low-Affinity Polyreactive Antibodies***.*

ROCH (A.). *Paid Advertising Campaign.*

ROCH (A.). *Student Awareness Program.*

THIBAUT (L.), BAZIN (R.), ST-LAURENT (M.), LEMIEUX (R.). *Intrinsic Affinity of IgM and IgG Blood Group Antibodies Affects Their Relative Reactivity***.*

THIBAUT (L.), LEMIEUX (R.), BEAUSÉJOUR (A.). *Development of an IgA-Specific ELISA for the Screening of IgA-Deficient Blood Donors***.*

INTERNATIONAL SYMPOSIUM ON PRION

DISEASES AND RELATED PROCESSES

ANNECY, NOVEMBER 2000

POSTER

JUNG (D.), LEMIEUX (R.), DROUIN (M.). *Development of a Suitable Assay for Large Scale PRNP M/V Genotyping at Codon 129.*

FORUM OF THE NATIONAL

BLOOD SAFETY COUNCIL

VANCOUVER, MARCH 2001

DÉCARY (F.). *Achieving Plasma Self-Sufficiency in Québec.*

CORPORATE PRESENTATIONS

BÉLISLE (L.). *Concepts de base en assurance de la qualité,* Canadian Society for Transfusion Medicine Conference, Québec City, May 2000.

GAGNON (L.). *A Puzzle That Falls into Place: Progesa,* International Mak Users (IMU), July 2000.

ROCH (A.). *Universal Leukoreduction Flow Process at HÉMA-QUÉBEC,* American Red Cross, Minneapolis, July 2000.

DÉCARY (F.). *Course on strategic management,* given at the École nationale d'administration publique, Montréal, November 2000.

ROCH (A.). *Universal Leukoreduction Flow Process at HÉMA-QUÉBEC,* Pall Medical Interactive Forum, Washington, November 2000.

DÉCARY (F.). *Change Management Paradigm Shift,* presentation to Health Canada, Aylmer, January 2001.

DÉCARY (F.). *HÉMA-QUÉBEC Update,* presentation to Canadian Blood Services, Ottawa, January 2001.

ROCH (A.). *Comme vous, nous gérons serré,* Chambre de commerce du Grand Joliette, March 2001.

ROCH (A.). *Red Cells Supply at HÉMA-QUÉBEC,* Anemia Institute Toronto, March 2001.

DÉCARY (F.). *Improvisation maîtrisée: comment conjuguer efficacement planification et spontanéité,* talk given to the Financial Management Institute of Canada, Montréal chapter, May 2001.

C ONTINUING MEDICAL EDUCATION

GOLDMAN (M.). *Hepatitis C Lookback in Canada*, 26th Congress of the ISBT, Vienna, July 2000.

GERMAIN (M.). *Maladies à prions, variante du Creutzfeldt-Jakob: état de la situation et conséquences pour la transfusion sanguine au Québec*, presentation to the Groupe de recherche en épidémiologie, Hôpital Saint-Sacrement, Québec City, October 2000.

GERMAIN (M.). *L'application du principe de précaution en transfusion sanguine*, presentation as part of the Journées annuelles de santé publique, Montréal, November 2000.

GERMAIN (M.). *Les infections transmissibles par la transfusion en l'an 2000: mesures de sécurité appliquées par le fournisseur*, presentation to the CUSE interdepartmental medical conferences, December 2000.

GOLDMAN (M.). *La médecine transfusionnelle—Quoi de neuf?*, Hôpital Pierre-Boucher, December 2000.

* Poster abstract published in *Transfusion Medicine*, 3, 2000.

** Paper abstract published in *Experimental Hematology*, 28(2000), 31-131.

*** Paper and poster abstracts published in *Transfusion Medicine*, 40(10S), October 2000.